Jonsson Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).
Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.
Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.
Top-decile sponsor footprint
Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
321 total, page 7 of 7
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
NCT00006083
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
NCT00004879
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
NCT00004132
Comparison of Screening Tests in Detecting Cervical Neoplasia
NCT00039312
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00004889
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
NCT00004865
Vaccine Therapy in Treating Patients With Liver Cancer
NCT00005629
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
NCT00003963
Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00005079
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
NCT00005082
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
NCT00003748
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
NCT00003410
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00003409
Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases
NCT00003324
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
NCT00003143
Diet and Estrogen Metabolism in Postmenopausal Women
NCT00003098
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
NCT00005617
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
NCT00003225
Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer
NCT00006341
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
NCT00004880
Radiation Therapy Following Surgery to Remove Brain Metastases
NCT00003320
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 100 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Jonsson Comprehensive Cancer Center pipeline
61 recruiting of 321 indexed (19% open); 164 completed (51%).
Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).
Top condition: Prostate Carcinoma (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 321 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Allergan · 314 trials · 0% recruiting
- Genentech · 332 trials · 7% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Verastem · 19% recruiting · 21 trials
Related
What to do with this Jonsson Comprehensive Cancer Center page
321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.
- 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.